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Abstract
Background: Fimasartan is the ninth angiotensin receptor blocker to be developed. However, it has not yet been
evaluated for reno-protective effects in hypertensive diabetic chronic kidney disease (CKD). The target blood pressure
(BP) for hypertensive diabetic CKD is also a controversial topic. This trial was designed to assess the reno-protective
effects of fimasartan compared to those of losartan as a primary outcome. This study also compares the two drugs
with regard to cardiovascular and renal outcomes in accordance with target systolic BP (SBP) (as secondary outcomes).
Methods: This study is a prospective, phase III, randomized, double-blind, active-controlled, non-inferiority,
four-parallel group, dose-titration, multicenter trial. We recruit patients with hypertensive diabetic CKD with
overt proteinuria. Participants will be randomized into four groups (1:1:1:1): fimasartan standard SBP control
(SBP < 140 mmHg); fimasartan strict SBP control (SBP < 130 mmHg); losartan standard SBP control; and
losartan strict SBP control. After 24 weeks, all individuals are treated with fimasartan for an additional
120 weeks in an open-label design, maintaining their assigned SBP control groups as randomized. The
primary endpoint is the rate of change in proteinuria, which is assessed using the spot urine albumin–
creatinine ratio at 24 weeks. The secondary endpoints are the cardiovascular and renal outcomes at
144 weeks compared between the strict SBP and standard SBP control groups.
Discussion: The FANTASTIC is a clinical study to provide: (1) the reno-protective effect of fimasartan; and
(2) the target BP to reduce adverse outcomes in hypertensive diabetic CKD with overt proteinuria.
Trial registration: Clinicaltrials.gov, NCT02620306. Registered on 1 December 2015.
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Background
Hypertension affects approximately 40% of adults world-
wide [1] and about two-thirds of patients with diabetes
have concomitant hypertension [2]. Both hypertension
and diabetes have a variety of vascular complications, in-
cluding macrovascular and microvascular effects. The
macrovascular complications of hypertension and diabetes
include coronary artery disease, stroke, and peripheral vas-
cular disease. The microvascular complications include
retinopathy, nephropathy, and neuropathy. Hypertension
and diabetes also increase the risk of developing new-
onset chronic kidney disease (CKD) [3]. The progression
of CKD is accompanied by microvascular complications.
CKD increases a patient’s risk of stroke, coronary artery
disease, and all-cause mortality. The annual mortality rate
of those patients who progress to require dialysis is about
10–20% [4, 5].
Given the association between CKD and cardiovascular
disease, it is important to suppress CKD progression in pa-
tients with both hypertension and diabetes. The degree of
baseline proteinuria is correlated to the future progression
of CKD [6–8]. High albuminuria was shown to be associ-
ated with increased risk of myocardial infarction, stroke,
first hospitalization for heart failure, unstable angina, cor-
onary or peripheral revascularization, and cardiovascular
death [9]. Recent evidence has shown that reducing pro-
teinuria can prevent the progression of CKD. Angiotensin
II receptor blockers (ARB) have also been shown to reduce
CKD progression of CKD [10–14]. Most hypertension
guidelines recommend that angiotensin converting enzyme
inhibitors (ACEI) or ARBs be used in patients with hyper-
tensive diabetes [15–17]. There are few studies that directly
compare the renal efficacy of two ARBs in hypertensive dia-
betes. In one comparison study of hypertensive type 2 dia-
betic patients with overt nephropathy, telmisartan were
found to have similar renal efficacy to valsartan [18]. In an-
other comparison study, telmisartan was found to be super-
ior to losartan at reducing the geometric mean urinary
protein–creatinine ratio without a change in blood pressure
(BP), dietary sodium, or estimated glomerular filtration rate
(eGFR) [19]. Therefore, although ARBs have a reno-
protective class effect, there are relative differences in each
drug’s efficacy.
Fimasartan was the ninth ARB approved for the treat-
ment of hypertension by the Korean Ministry of Food and
Drug Safety in 2010; it entered the market in 2011 [20].
Its chemical characteristics are as follows: 2-n-butyl-5-
dimethylaminothiocarbonyl methyl-6-methyl-3-([2’-(1H-
tetrazol-5-yl) biphenyl-4-yl] methyl) pyrimidin-4(3H)-
one); molecular formula, C27H31N7OS; molecular
weight, 501.65; formally known as BR-A-657. Despite the
proven antihypertensive effect, however, the renal efficacy
and safety of fimasartan in hypertensive diabetic CKD
have not been studied or compared to those of other
ARBs. Therefore, this randomized multicenter clinical trial
compares the renal efficacy and safety of fimasartan to
those of losartan, which has already been shown to have a
renal protective effect [12].
The target BP in diabetic CKD remains controversial.
There are inconsistencies in the current guidelines regard-
ing target BP for patients with diabetic CKD from KDIGO
(Kidney Disease Improving Global Outcomes), ESC
(European Society of Cardiology), and JNC (Joint National
Committee) 8 [15, 16, 21]. The current KDIGO guideline
recommends that the target goal is a systolic BP (SBP) <
130 mmHg and diastolic BP (DBP) < 80 mmHg in diabetic
CKD, with a urine albumin excretion > 30 mg/day. [21]
The JNC 8 panel recommends that hypertensive adults
with diabetic or non-diabetic CKD keep their BP < 140/
90 mmHg. [15]
Thus, the purpose of the present study, FimAsartaN pro-
TeinuriA SusTaIned reduCtion in comparison with losartan
in diabetic chronic kidney disease (FANTASTIC) trial, is to
investigate the reno-protective effect of fimasartan in com-
parison with losartan in patients within a diabetic CKD
group and we also aim to evaluate the long-term effect of
strict SBP control on renal and cardiovascular outcomes in
comparison with standard SBP control.
Methods
Study design
The FANTASTIC study is a randomized, multi-centered,
double-blind, four-parallel group, dose-titration, phase III
study. This study was designed to compare the efficacy of
fimasartan (study group) and losartan (control group) with
regard to the rate of change in proteinuria. It also com-
pares the adverse outcomes between strict BP control and
standard BP control in patients with hypertensive diabetic
CKD with overt proteinuria. Forty clinical research centers
(19 nephrology, 14 cardiology, and seven endocrinology)
participated in this trial and all research centers are com-
prised of the tertiary university hospital. This study is
sponsored by an investigator-initiated grant by Boryung
Pharmaceutical Co., Ltd. It was registered at http://
www.clinicaltrials.gov/ before participant recruitment
(NCT02620306). All participants will provide written in-
formed consent based on documents approved by each
university Institutional Review Board.
Study eligibility
Inclusion and exclusion criteria
Patients are screened for the following four required
conditions: high BP; CKD; overt proteinuria (or macroal-
buminuria); and type 2 diabetes mellitus. The detailed
inclusion criteria are described in Table 1. The exclusion
criteria are described in Table 2. Finally, after learning
about the study, patients voluntarily provided written
consent to participate.
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Screening
Included individuals go through a single-blind placebo
run-in period for at least four weeks. During this period,
any treatment with ACEI/ARBs for hypertension will be
discontinued. However, other antihypertensive drugs are
administered without changing the regimens or doses.
During the placebo run-in period, the participant is
instructed to measure his/her own BP with a provided
oscillometric automatic device more than once a day. In-
dividuals are instructed to visit the study site in the
event of SBP ≥ 180 mmHg or onset of any symptoms of
suspected hypertension (e.g. headache, dyspnea, chest
discomfort, vomiting, and neurologic symptoms). In this
situation, additional antihypertensive drugs (other than
ACEIs/ARBs) are introduced or adjustments were made
to the doses of the patient’s other medications as appro-
priate. After the placebo run-in period is completed for
at least four weeks, tests for eligibility assessment are
performed at the visit before baseline (Visit 2).
Randomization
The individuals are finally selected at baseline (Visit 3).
An independent group not involved with study imple-
mentation creates a randomization schedule for study
drug labelling and randomization is stratified by study
site. Eligible participants are randomized into one of the
following four groups in a 1:1:1:1 ratio using the inter-
active web-based randomization system, Fimasartan
group A, Fimasartan group B, Losartan group A, and
Losartan group B. Group A is a standard BP control
group (SBP < 140 mmHg), while Group B is a strict BP
control group (SBP < 130 mmHg). The randomized par-
ticipants are treated with the investigational product
(fimasartan or losartan) corresponding to each treatment
group for 24 weeks on double-blind (physician and pa-
tient). After that, all individuals take fimasartan for an
additional 120 weeks in an open-label study conducted
with two groups (in accordance with BP control). The
eligible participants provide written consent for partici-
pation in the open-label study and clinical study (Fig. 1).
Table 1 Inclusion criteria
Age: 19–70 years
Screening visit (Visit 1)
Hypertension in treatment-naïve patients
140 mmHg≤ SBP < 180 mmHg and DBP < 110 mmHg
Hypertension with treatment, including ACEI/ARB
130 mmHg≤ SBP < 180 mmHg and DBP < 110 mmHg
eGFR≥ 30 mL/min/1.73 m2 (by MDRD) within the past six months
Urine protein (within the past six months)
ACR ≥ 300 mg/g (or mg/day)
or protein–creatinine ratio≥ 500 mg/g (or mg/day)
Type 2 diabetes mellitus (diagnosed > 3 months prior) on
medications with
no changes in medication regimen/dose within the last three
months
Baseline visit (Visit 3)
Hypertension
140 mmHg≤ SBP < 180 mmHg and DBP < 110 mmHg
eGFR≥ 30 mL/min/1.73 m2 (by MDRD)
Urine protein: ACR≥ 300 mg/g in spot urine
Type 2 diabetes without regimen change during placebo run-in
period
SBP systolic blood pressure, DBP diastolic blood pressure, ACEI angiotensin
converting enzyme inhibitor, ARB angiotensin receptor blocker, ACR albumin–
creatinine ratio, eGFR estimated glomerular filtration rate, MDRD Modification
of Diet in Renal Disease
Table 2 Exclusion criteria
Secondary or malignant hypertension
Inter-arm BP difference: SBP > 20 mmHg or DBP > 10 mmHg
Symptomatic orthostatic hypotension
Cardiovascular history
MI, congestive heart failure (NYHA class III or IV), CABG, PTCA, or
angina < 3 months before enrollment
Severe cerebrovascular disease (stroke, cerebral infarction, or
cerebral hemorrhage)
Arrhythmia (significant ventricular tachycardia, atrial fibrillation, or
atrial flutter)
Significant valvular disease: aortic stenosis or mitral stenosis
Hypertrophic cardiomyopathy
Type 1 DM or HbA1c > 9% at screening
Significant renal or hepatic disease
Dialysis, cirrhosis, biliary tract obstruction, cholestasis, or liver failure
eGFR (MDRD) < 30 mL/min/1.73 m2, hyperkalemia (>5.5 mmol/L) or
hypokalemia (<3.5 mmol/L)
AST or ALT > 3 times the upper limit of normal
Any chronic inflammatory disease requiring chronic anti-inflammatory
treatment (including rheumatoid arthritis, systemic lupus erythemato-
sus, or connective tissue disease)
Moderate or malignant retinopathy < 6 months before enrollment
(e.g. moderate or severe non-proliferative diabetic retinopathy and
proliferative diabetic retinopathy)
Surgical or medical disease that may affect drug absorption,
distribution, metabolism, or excretion
Cancer history with current treatment or treatment within five years
Pregnancy, childbearing potential without adequate contraception, or
breast-feeding
Previous hypersensitivity reaction to renin-angiotensin system
inhibitors
Alcohol or drug abuse within the previous two years
Poor compliance during placebo run-in period: < 70%
SBP systolic blood pressure, DBP diastolic blood pressure, MI myocardial
infarction, NYHA New York Heart Association, CABG coronary artery bypass
graft, PTCA percutaneous coronary angioplasty, DM diabetes mellitus, eGFR
estimated glomerular filtration rate, MDRD Modification of Diet in Renal
Disease, AST aspartate transaminase, ALT alanine transaminase
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Methods of dose administration
Either the study drug (fimasartan 60 mg/day) or control
drug (losartan 50 mg/day) is administered at the time of
randomization and maintained during the double-blind
study period. The dose is titrated if the patient BP dose not
meets the targeted level at each visit after Visit 4. The dose
titrations are made at the discretion of the investigator
based on the measured SBP. Fimasartan 60 mg or losartan
50 mg are uptitrated to fimasartan 120 mg or losartan
100 mg, respectively. At subsequent visits, additional anti-
hypertensive therapy is added, excluding ACEIs or ARBs, in
the following order: dihydropyridine calcium channel
blockers; diuretics; β-blockers; α-blockers; and direct vaso-
dilators (see Fig. 1). When additional antihypertensive drugs
are administered, the dose is increased one level at a time.
If the additional medication is still needed before the next
visit because of continued uncontrolled BP, the dose can be
titrated to the next level by making an unscheduled visit.
This decision is made by the investigator. The investigator
can also change the order of additional drugs administered
in consideration of any antihypertensive drug that the sub-
ject have already taken. The drug dose can also be de-
creased in order to satisfy the BP control criteria or in the
case of adverse events. However, the doses of other antihy-
pertensive drugs (excluding fimasartan/losartan) are the
first to be decreased when doses are adjusted. The doses of
fimasartan and losartan are not changed if possible. Any in-
dividuals who cannot tolerate the BP control process does
not continue the clinical study.
Follow-up
The participants visit the hospital a total of seven times
during the study: the screening visit; visit before base-
line; baseline visit; visit 4 (four weeks); visit 5 (eight
weeks); visit 6 (12 weeks); and visit 7 (24 weeks). Sched-
uled tests and evaluations are performed at each visit.
The BP control is single-blinded in order to allow identi-
fication of the strict BP control and standard BP control
Fig. 1 Flow chart of FANTASTIC study. The FANTASTIC study consists of two phases: four-parallel double-blind period to investigate the reno-protective
effect of fimasartan and two-parallel open-label period for prognosis in accordance with target BP. a Standard BP control group (systolic BP < 140 mmHg). b
Strict BP control group (systolic BP < 130 mmHg). FIM fimasartan, LOS losartan, CCB calcium channel blocker, ACR albumin–creatinine ratio, CV cardiovascular,
SBP systolic blood pressure
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groups, because the investigator should check the indi-
vidual’s target BP during each follow-up. After visit 7, a
two-parallel study is performed to confirm the efficacy
and safety of the drug in the standard and strict BP con-
trol groups. The individuals participate in visits every
12 weeks (36, 48, 60, 72, 84, 96, 108, 120, 132, and
144 weeks) for efficacy and safety assessment (Fig. 2).
All of the participants take fimasartan during the open-
label study period. The individuals taking losartan dur-
ing the double-blind study period will be change their
drug to the equivalent dose of fimasartan. If the targeted
BP cannot be reached, the dose titration method will be
used in the double-blind study period (see Fig. 1).
Blood pressure and biochemical measurements
The reported BP is the mean BP from three measure-
ments on the selected arm. Proteinuria is measured from
the spot urine albumin–creatinine ratio (ACR) based on
the first urine in the morning. The eGFR is calculated
using the modified Modification of Diet in Renal Disease
(MDRD) equation [22].
Primary and secondary endpoints
The primary endpoint is the rate of change in proteinuria
in the fimasartan group and the losartan group from base-
line to 24 weeks.
The major secondary endpoints are cardiovascular com-
posite endpoints and renal composite endpoints. The
cardiovascular composite endpoints are defined as the time
to the first occurrence of any of the following (in accord-
ance with the BP control criteria): myocardial infarction;
stroke; hospitalization due to heart failure; unstable angina;
coronary revascularization; peripheral revascularization; or
all-cause mortality. The renal composite endpoints include
any of the following (in accordance with the BP control cri-
teria): the time to serum creatinine concentration doubling
from baseline; the time to progression to end stage renal
disease (ESRD) (as confirmed by the initiation of long-term
dialysis or renal transplantation); and all-cause mortality.
Other secondary endpoints
The other secondary endpoints are summarized as fol-
lows: (1) the rate of change in proteinuria in the fimasar-
tan and losartan groups from baseline to weeks 4, 8, and
12; (2) the change in proteinuria in the fimasartan and
losartan groups from baseline to weeks 4, 8, and 12; (3)
the rate and amount of change in eGFR in the fimasar-
tan and losartan groups from baseline to weeks 4, 8, 12,
and 24; (4) the proportion of individuals who developed
microalbuminuria (urine ACR < 300 mg/g) in the fima-
sartan and losartan groups at weeks 4, 8, 12, and 24; (5)
the proportion of individuals with ≥ 30% decrease in al-
buminuria in the fimasartan and losartan groups from
baseline to weeks 4, 8, 12, and 24; (6) the proportion of
participants with ≥ 50% decrease in eGFR in the fimasar-
tan and losartan groups from baseline to weeks 4, 8, 12,
Fig. 2 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) figure. BP blood pressure, BUN blood urea nitrogen, ECG
electrocardiography, eGFR estimated glomerular filtration rate
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and 24: (7) the rate and amount of change in albumin-
uria from baseline to weeks 4, 8, 12, 24, 36, 48, 72, 96,
120, and 144 in accordance with the BP control criteria;
(8) the rate and amount of change in eGFR from base-
line to weeks 4, 8, 12, 24, 36, 48, 72, 96, 120, and 144 in
accordance with the BP control criteria; (9) the propor-
tion of individuals with a change in microalbuminuria
(urine ACR < 300 mg/g) at weeks 4, 8, 12, 24, 36, 48, 72,
96, 120, and 144 in accordance with the BP control cri-
teria; (10) the proportion of participants with ≥ 30% de-
crease in albuminuria from baseline to weeks 4, 8, 12,
24, 36, 48, 72, 96, 120, and 144 in accordance with the
BP control criteria; and (11) the proportion of individ-
uals with ≥ 50% decrease in eGFR from baseline to weeks
4, 8, 12, 24, 36, 48, 72, 96, 120, and 144 in accordance
with the BP control criteria.
Safety assessment
The safety assessments include laboratory tests
(hematology/blood chemistry, urinalysis), electrocardiogram,
chest X-ray, physical examination, orthostatic hypotension
assessment, and changes in body weight and pulse rate. At
least once after randomization, any adverse events that oc-
curred after administration of the investigational product
are assessed. All adverse events are summarized and pre-
sented by treatment group with respect to severity, relation-
ship to the investigational product, and outcome.
Data collection and management
The electronic case report form (eCRF) is developed by
supervision of Boryung pharm’s data management (DM)
team before first enrollment. Data entry will be performed
by the investigators and clinical research coordinators at
the participating sites using a web-based database: Medi-
data Rave™ (Medidata Solutions, Inc., http://www.mdsol.-
com). Rave™ is a commercial system designed to capture,
manage, and report clinical research data. And Medidata
Rave™ supports electronic record and electronic signature
requirements, audit trail including US 21 CRF part 11.
Through this system, each participating site is assigned a
unique code, as identified by the study team. All staff is
trained in using eCRF in advance and then is given each
EDC (Electronic Data Capture)’s role. The DM team also
provided at each site on the data entry and data monitor-
ing guide book. All participating sites will use the same
CRFs. If responses to the initial inclusion and exclusion
criteria provided by the individual performing the data
entry fulfill study criteria, the system will dynamically gen-
erate randomization and data validation process. All DM
tasks are performed by Data Management Plan (DMP).
We designed the eCRF and set up all DM process accord-
ing the protocol and DMP documents. The DMP include
all staff ’s role and responsibility, each step’s definition and
process, data backup and transfer, etc. Auto and manual
data queries are generated by CRA (Clinical Research As-
sociates) or a DM person and will be resolved by
CRCs (Clinical Reseach Coordinators) and investigators.
Through this iterative process, we will make the data clean
and finally perform database lock. All database backup of
eCRF will be done in real time by Medidata’s Houston
data center and Boryung pharm’s database system.
Statistics
In order to achieve a statistical power of 80%, the sample
size assumed a non-inferiority margin of 18% (based on
two-sided t test and a significance level of 0.025). This is
based on the rate of change in proteinuria from baseline
(Week 0) to week 24 of both losartan and fimasartan
groups with a standard deviation of 62% [10, 12–14, 23].
Based on the assumption of a drop-out rate of 20%, a
total of 468 patients are needed for randomization (with
234 patients per treatment arm).
The primary efficacy assessment finds that the fimasar-
tan group is not inferior to the losartan group if the
lower limit of a 95% two-sided confidence interval for
the difference in the rate of change in proteinuria at
week 24 between the fimasartan and losartan groups
(control group - study group) is > − 18%. This is defined
as the non-inferiority margin.
The major secondary efficacy assessment is determined
by the incidence of combined cardiovascular and renal
composite endpoints and is assessed using Kaplan–Meier
curves, according with target BP at 144 weeks. The median
survival time and confidence interval for the median sur-
vival time are presented. The log-rank test is used to com-
pare the groups. Other secondary efficacy assessments are
determined using the following methods. For continuous
variables, descriptive statistics (number of individuals,
mean, standard deviation, median, minimum, and max-
imum) for each time point are provided according to treat-
ment group or the BP control criteria. The t-test is used to
compare the inter-group difference in the rate of change.
The inter-group difference in the amount of change is
tested using the analysis of covariance, with the baseline
values as covariates and the treatment groups as factors.
The least squared mean and standard error are provided
for each group. Frequencies and ratios are provided for cat-
egorical variables such as the proportion of individuals. For
categorical variables, the Chi-square test, Fisher’s exact test,
or Cochran–Mantel–Haenszel test is performed.
The safety analysis is based on adverse events, laboratory
abnormalities, electrocardiography, chest X-rays, orthostatic
hypotension assessments, and abnormal changes in body
weight and pulse. Appropriate statistical analysis methods
are used to compare groups with regard to differences in
the rate of adverse events, abnormal laboratory values, or
other parameters. Either the Chi-square test or Fisher’s
exact test is used to assess differences in the incidence of
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adverse events between the groups. Continuous data, in-
cluding laboratory values (hematology/blood chemistry,
urinalysis) and vital signs (pulse rate, body weight, etc.), are
presented in the form of descriptive statistics (mean, stand-
ard deviation, minimum, maximum, and median) by group
and visit. Either a paired t-test or the Wilcoxon signed-rank
test is used to test the intra-group difference in the continu-
ous data between baseline and after drug administration. In
addition, the two-sample t-test and Wilcoxon rank sum test
is performed to test inter-group differences (in continuous
variables) from baseline to after drug administration.
Among all of the laboratory values, categorical data are di-
vided into normal and abnormal results. The inter-group
differences are tested using the Chi-square test or Fisher’s
exact test. The McNemar’s test is used to compare differ-
ences in the categorical data between baseline and after
drug administration.
Discussion
This study compares the changes in proteinuria between
fimasartan and losartan groups in patients with hyperten-
sive diabetic CKD with overt proteinuria. It also compares
the differences in cardiovascular and renal outcomes in
accordance with the target SBP goal.
The majority of hypertensive guidelines recommend
treating patients with diabetes or CKD with ACEIs or ARBs
because of the reno-protective effect of RAAS (Renin
Agiogtensin Aldosterone System) blockade [15–17]. How-
ever, there are few studies that directly compare the reno-
protective effect of different ARB agents in these patients.
In the VIVALDI study, telmisartan 80 mg and valsartan
160 mg had similar efficacy with regard to changes in 24-h
proteinuria [18]. In contrast, in the AMADEO study, telmi-
sartan 80 mg was superior to losartan 100 mg with regard
to the change in the spot urine protein–creatinine ratio
[19]. All of the patients included in the above two studies
had diabetic CKD with overt proteinuria and had SBP >
130 mmHg or DBP > 80 mmHg. Telmisartan’s superiority
over losartan may be a result of its longer half-life, higher li-
pophilicity, and stronger binding affinity for the angiotensin
II type 1 receptor compared to those of losartan [19].
The chemical composition of fimasartan includes a
bioisosteric replacement of the imidazole part of losartan
with pyrimidin-4(3H)-one [24]. Fimasartan has theoret-
ically similar lipophilicity and half-life to those of losar-
tan [25]. However, fimasartan has higher potency and
stronger efficacy than does losartan [26]. Losartan has
already been shown to have a reno-protective effect,
characterized by reduced proteinuria and a significant
delay in the progression of nephropathy in patients with
diabetic nephropathy. These reno-protective effects were
also associated with a reduction in albuminuria in the
RENNAL study [6]. The present study was designed as a
non-inferiority trial to compare losartan and fimasartan
with regard to the rate of change in albuminuria and to
confirm the reno-protective effect of fimasartan.
The target BP level in diabetic CKD is controversial.
Previous studies, including the MDRD and African
American Study of Kidney Disease and Hypertension
(AASK), compared standard BP control with intensive BP
control in CKD. The MDRD study included patients with
non-diabetic CKD stage 3 or 4 and employed either stand-
ard target BP control (of ≤ 140/90 mmHg with mean arter-
ial pressure (MAP) ≤ 107 mmHg) or intensive BP control
(of 125/75 mmHg with MAP ≤ 92 mmHg). There was no
difference in the progression of CKD between the stand-
ard and intensive BP control groups [27]. However, in post
hoc analysis of the MDRD study, intensive BP control was
beneficial in the progression of CKD in accordance with
the degree of proteinuria. Patients with proteinuria of
0.25–1.0 g/d were advised to aim for a target BP of ap-
proximately < 130/80 mmHg [8].
AASK consisted of CKD stage 3 (GFR of 20–65 mL/
min/1.73 m2) in African Americans with hypertension.
The standard target BP was ≤ 140/90 mmHg (MAP ≤
107 mmHg), and intensive target BP was 125/75 mmHg
(MAP ≤ 92 mmHg). There was no difference in the pro-
gression of CKD between the standard and intensive BP
control groups [28]. However, the long-term AASK data
demonstrated that the intensive BP control group with
proteinuria (urine protein–creatinine ratio > 0.22) had a
lower incidence of ESRD than did the normal BP control
group [29]. These finding suggest that it is necessary to
adjust the target BP in CKD patients depending on the
degree of proteinuria.
The KDIGO guideline recommends that the target BP
goal in patients with diabetic CKD with urine albumin ex-
cretion > 30 mg/day is a SBP < 130 mmHg and DBP <
80 mmHg [21]. The ESC guidelines recommend target
goals of SBP < 140 mmHg in CKD or non-CKD, SBP <
130 mmHg when overt proteinuria is present, and DBP <
85 mmHg in diabetes [16]. However, in the Action to Con-
trol Cardiovascular Risk in Diabetes (ACCORD) trial, pa-
tients treated with intensive BP control (SBP < 120 mmHg)
and those with eGFR < 30 mL/min/1.73 m2 experienced
more hypotension than did those with standard BP control.
Intensive BP control also did not reduce the cardiovascular
outcomes [30]. This result is reflected in JNC 8. Panels of
JNC 8 recommend the same threshold for hypertensive
adults with diabetic or non-diabetic CKD at < 140/
90 mmHg [15].
The recent SPRINT (the Systolic Blood Pressure Inter-
vention Trial) study found that, among patients at high risk
for cardiovascular events, intensive BP control (SBP <
120 mmHg) resulted in lower rates of cardiovascular events
than did standard BP control (SBP < 140 mmHg). Approxi-
mately 28% of all patients with CKD and a GFR between 20
and < 60 mL/min/1.73 m2 in SPRINT (excluding those with
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diabetes and overt proteinuria) experienced no benefit with
regard to renal outcomes [31]. Although there was a benefit
in cardiovascular outcomes in CKD, such a result cannot
be generalized to all CKD patients because patients with
diabetes and proteinuria were excluded. Strict BP in this
study was defined as SBP < 130 mmHg. This value was
higher than the intensive control parameter employed in
the ACCORD study (SBP < 120 mmHg), but was the same
as that used in the ESC and KDIGO studies (SBP <
130 mmHg). This study addresses the question of target BP
in patients with hypertensive diabetic CKD with overt
proteinuria. This was a randomized, double-blind, active-
controlled, non-inferiority, four-parallel group, dose-
titration, multicenter study that evaluates the efficacy and
safety of fimasartan vs losartan in patients with hyperten-
sive diabetic CKD. It is expected to confirm whether there
is the reno-protective effect of fimasartan. It also addresses
the cardiovascular and renal outcomes of fimasartan in ac-
cordance with target BP as a strategy to reduce proteinuria
and adverse outcomes in patients with hypertensive dia-
betic CKD with overt proteinuria
Trial status
Recruitment began in November 2015 and 171 patients
(314 patients in screening) were randomized to October
2017. The recruitment is an ongoing process.
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Additional file 1: SPIRIT 2013 checklist: recommended items to address
in a clinical trial protocol and related documents. (DOC 102 kb)
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